A11100P

DMT-dA(bz) Pharmadite^®

• 別名: DMT-dA(bz) ホスホロアミダイト, N6-ベンゾイル-5'-O-(4,4'-ジメトキシトリチル)-2'-デオキシアデノシン-3'-O-[O-(2-シアノエチル)-N,N'-ジイソプロピルホスホロアミダイト]
• 実験式（ヒル表記法）: C₄₇H₅₂N₇O₇P
• CAS番号: 98796-53-3
• 分子量: 857.93
• MDL番号: MFCD00036314
• UNSPSCコード: 41116107
• PubChem Substance ID: 329770659
• NACRES: NA.51

特性

• 由来生物: non-animal source (no BSE/TSE risk)
• 品質水準: 300
• タイプ: for DNA synthesis
• 製品種目: Proligo Reagents
• アッセイ: ≥99.5% (reversed phase HPLC); >99.5% (³¹P-NMR)
• 形状: powder or granules
• テクニック: oligo synthesis: suitable
• 不純物: >= 170ppm, none detected (S/N <2.5); ≤0.1% P(III) 100-169ppm (³¹P-NMR); ≤0.1% single unspecified Imprity (reversed phase HPLC); ≤0.3% dA2 (reversed phase HPLC, DMT-dA(bz) cyanoethyl-H-posphonate); ≤0.3% dA3 (reversed phase HPLC, DMT-dA(bz) phosphoramidate); ≤0.30 wt. % water content (Karl Fischer); ≤0.5% P(V) -25-99ppm (³¹P-NMR); ≤3.0 wt. % residual solvent content
• 色: white to off-white
• 溶解性: soluble, clear
• 適合性: conforms to structure for H-NMR; conforms to structure for LC-MS
• 核酸プロファイル: base: deoxyadenosine; base protecting group: benzoyl; 2' protecting group: none; 5' protecting group: DMT; deprotection: standard
• 保管温度: 2-8°C
• SMILES記法: COc1ccc(cc1)C(OC[C@H]2O[C@H](C[C@@H]2OP(OCCC#N)N(C(C)C)C(C)C)n3cnc4c(NC(=O)c5ccccc5)ncnc34)(c6ccccc6)c7ccc(OC)cc7
• InChI: 1S/C47H52N7O7P/c1-32(2)54(33(3)4)62(59-27-13-26-48)61-40-28-42(53-31-51-43-44(49-30-50-45(43)53)52-46(55)34-14-9-7-10-15-34)60-41(40)29-58-47(35-16-11-8-12-17-35,36-18-22-38(56-5)23-19-36)37-20-24-39(57-6)25-21-37/h7-12,14-25,30-33,40-42H,13,27-29H2,1-6H3,(H,49,50,52,55)/t40-,41+,42+,62?/m0/s1
• InChI Key: GGDNKEQZFSTIMJ-AKWFTNRHSA-N

詳細

詳細

DMT-dA(bz) Pharmadite^® is a Pharmadite^® product line that represents a new class of standard protected DNA phosphoramidites that are designed with highly controlled impurity profiles and exceptional overall purity. Pharmadite phosphoramidites are characterized by their exceptional purity and well-defined impurity profile. In particular, they are essentially free from contaminants that interfere in coupling reactions, such as other nucleosidic or non-nucleosidic phosphoramidites (P(III)-contaminants). All remaining impurities in Pharmadite phosphopramidites, if present, are identified, characterized, and quantified. The impact of any such defined impurities on the synthesis of oligonucleotides is well understood and has been shown to be insignificant.

アプリケーション

Pharmadite products fulfill all requirements of starting materials for themanufacture of active pharmaceutical ingredients as defined in the EMEA "Note for guidance on the chemistry of the new active substance," making them suitable building blocks for oligonucleotide drugs.

その他情報

Pharmadite phosphoramidites are manufactured in scales of up to multi-hundred kilos, under certified ISO 9001 quality systems.

法的情報

Pharmadite is a registered trademark of Merck KGaA, Darmstadt, Germany

安全性情報

• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable